Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Myeloid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 12Multiple Myeloma 11Recurrence 8Lymphoma, Large B-Cell, Diffuse 4Sarcoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Endometrial Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, B-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Congenital Abnormalities 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors 1Sarcoma, Endometrial Stromal 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Neurofibrosarcoma 1

Interventions

Rituximab 193Cyclophosphamide 177fludarabine phosphate 151Peripheral Blood Stem Cell Transplantation 89fludarabine 77Mycophenolic Acid 70Filgrastim 63Whole-Body Irradiation 59Tacrolimus 55Lenalidomide 54Cyclosporine 54ibrutinib 53Bendamustine Hydrochloride 50Busulfan 49Melphalan 45Radiotherapy 42Etoposide 42Alemtuzumab 42Antilymphocyte Serum 40ofatumumab 35obinutuzumab 33Methotrexate 33venetoclax 27Cytarabine 25sargramostim 23Granulocyte Colony-Stimulating Factor 22Dexamethasone 21Methylprednisolone 19Bortezomib 19Chlorambucil 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Leukemia, Lymphocytic, Chronic, B-Cell × selinexor × Clear all
NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
34 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
286 enrolled 26 charts
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡